TY - JOUR
T1 - Temporal trends in venous thromboembolism after radical cystectomy
AU - Lyon, Timothy D.
AU - Tollefson, Matthew K.
AU - Shah, Paras H.
AU - Bews, Katherine
AU - Frank, Igor
AU - Karnes, R. Jeffrey
AU - Thompson, R. Houston
AU - Habermann, Elizabeth B.
AU - Boorjian, Stephen A.
N1 - Funding Information:
This work was supported in part by the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/8
Y1 - 2018/8
N2 - Purpose: To determine whether the rate of venous thromboembolism (VTE) following radical cystectomy (RC) is changing overtime. Materials and methods: The American College of Surgeons National Surgical Quality Improvement Program database was used to identify patients who underwent RC for bladder cancer from 2011 to 2016. VTE was defined as pulmonary embolism or deep vein thrombosis within 30 days of RC. VTE rate by year was assessed using the Cochran-Armitage test for trend. Associations between patient features and VTE were evaluated with multivariable logistic regression. Results: A total of 8,241 patients undergoing RC were identified, of whom 348 (4.2%) were diagnosed with VTE. VTE was diagnosed at a median of 13 days (IQR: 7–19) after RC, with 171 (49%) occurring after hospital discharge. Notably, the rate of VTE after RC was found to significantly decrease over time, from 5.1% in 2011 to 2.8% in 2016 (P = 0.001). On multivariable analysis, clinical factors significantly associated with increased odds of VTE included congestive heart failure (odds ratio [OR] = 2.83, P = 0.01), prolonged operative time (OR: 1.48–1.56, P = 0.02–0.01), and receipt of a perioperative blood transfusion (OR = 1.27; P = 0.04). When postoperative complications were adjusted for, sepsis/septic shock (OR = 2.37, P<0.001) and perioperative infection (OR = 1.74, P<0.001) were likewise found to be associated with VTE. Conclusions: The rate of VTE after RC significantly decreased in recent years, potentially reflecting improvements in perioperative care. The specific casual factors underlying this trend, in addition to efforts to address identified risk factors for VTE, warrant continued study.
AB - Purpose: To determine whether the rate of venous thromboembolism (VTE) following radical cystectomy (RC) is changing overtime. Materials and methods: The American College of Surgeons National Surgical Quality Improvement Program database was used to identify patients who underwent RC for bladder cancer from 2011 to 2016. VTE was defined as pulmonary embolism or deep vein thrombosis within 30 days of RC. VTE rate by year was assessed using the Cochran-Armitage test for trend. Associations between patient features and VTE were evaluated with multivariable logistic regression. Results: A total of 8,241 patients undergoing RC were identified, of whom 348 (4.2%) were diagnosed with VTE. VTE was diagnosed at a median of 13 days (IQR: 7–19) after RC, with 171 (49%) occurring after hospital discharge. Notably, the rate of VTE after RC was found to significantly decrease over time, from 5.1% in 2011 to 2.8% in 2016 (P = 0.001). On multivariable analysis, clinical factors significantly associated with increased odds of VTE included congestive heart failure (odds ratio [OR] = 2.83, P = 0.01), prolonged operative time (OR: 1.48–1.56, P = 0.02–0.01), and receipt of a perioperative blood transfusion (OR = 1.27; P = 0.04). When postoperative complications were adjusted for, sepsis/septic shock (OR = 2.37, P<0.001) and perioperative infection (OR = 1.74, P<0.001) were likewise found to be associated with VTE. Conclusions: The rate of VTE after RC significantly decreased in recent years, potentially reflecting improvements in perioperative care. The specific casual factors underlying this trend, in addition to efforts to address identified risk factors for VTE, warrant continued study.
KW - Bladder cancer
KW - Health services research
KW - Radical cystectomy
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85048214808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048214808&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2018.05.015
DO - 10.1016/j.urolonc.2018.05.015
M3 - Article
C2 - 29885792
AN - SCOPUS:85048214808
SN - 1078-1439
VL - 36
SP - 361.e15-361.e21
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 8
ER -